Do analysts recommend IMCC or GOVX?

GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 12,611.86%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than IM Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, IMCC or GOVX?

IM Cannabis has higher revenue and earnings than GeoVax Labs. IM Cannabis is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IM Cannabis $39.17M 0.04 -$8.10M -$1.75 N/A GeoVax Labs $852.28K 4.81 -$21.47M -$19.12 N/A

Is IMCC or GOVX more profitable?

GeoVax Labs has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. IM Cannabis' return on equity of -585.96% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets IM Cannabis -27.65% -585.96% -39.96% GeoVax Labs N/A -709.52% -399.33%

Does the media favor IMCC or GOVX?

In the previous week, IM Cannabis had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for IM Cannabis and 2 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.58 beat IM Cannabis' score of 0.22 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CNSP or IMCC?

CNS Pharmaceuticals currently has a consensus target price of $20.00, suggesting a potential upside of 323.73%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe CNS Pharmaceuticals is more favorable than IM Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CNSP or IMCC?

In the previous week, CNS Pharmaceuticals and CNS Pharmaceuticals both had 3 articles in the media. CNS Pharmaceuticals' average media sentiment score of 0.41 beat IM Cannabis' score of 0.22 indicating that CNS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CNS Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CUPR or IMCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, CUPR or IMCC?

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than IM Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $49.89K 126.79 -$3.63M N/A N/A IM Cannabis $39.17M 0.04 -$8.10M -$1.75 N/A

Does the media prefer CUPR or IMCC?

In the previous week, Cuprina Holdings (Cayman) and Cuprina Holdings (Cayman) both had 3 articles in the media. Cuprina Holdings (Cayman)'s average media sentiment score of 0.96 beat IM Cannabis' score of 0.22 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cuprina Holdings (Cayman) 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IMCC or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, IMCC or BDRX?

IM Cannabis has higher revenue and earnings than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IM Cannabis $39.17M 0.04 -$8.10M -$1.75 N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Does the media refer more to IMCC or BDRX?

In the previous week, IM Cannabis and IM Cannabis both had 3 articles in the media. Biodexa Pharmaceuticals' average media sentiment score of 0.96 beat IM Cannabis' score of 0.22 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biodexa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate IMCC or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

IM Cannabis (IMCC) Competitors

$0.25 +0.02 (+7.06%)

Closing price 03:59 PM Eastern

Extended Trading

$0.24 -0.01 (-2.14%)

As of 04:25 PM Eastern

Compare

IMCC vs. GOVX, CNSP, CUPR, BDRX, and CDIO

Should you buy IM Cannabis stock or one of its competitors? MarketBeat compares IM Cannabis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IM Cannabis include GeoVax Labs (GOVX), CNS Pharmaceuticals (CNSP), Cuprina Holdings (Cayman) (CUPR), Biodexa Pharmaceuticals (BDRX), and Cardio Diagnostics (CDIO). These companies are all part of the "pharmaceutical products" industry.

How does IM Cannabis compare to GeoVax Labs?

IM Cannabis (NASDAQ:IMCC) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

IM Cannabis has higher revenue and earnings than GeoVax Labs. IM Cannabis is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.04	-$8.10M	-$1.75	N/A
GeoVax Labs	$852.28K	4.81	-$21.47M	-$19.12	N/A

GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 12,611.86%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, IM Cannabis had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for IM Cannabis and 2 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.58 beat IM Cannabis' score of 0.22 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GeoVax Labs has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. IM Cannabis' return on equity of -585.96% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-27.65%	-585.96%	-39.96%
GeoVax Labs	N/A	-709.52%	-399.33%

IM Cannabis has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.62, meaning that its share price is 262% more volatile than the broader market.

Summary

IM Cannabis beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.

How does IM Cannabis compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

CNS Pharmaceuticals has a beta of 3.06, suggesting that its share price is 206% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

In the previous week, CNS Pharmaceuticals and CNS Pharmaceuticals both had 3 articles in the media. CNS Pharmaceuticals' average media sentiment score of 0.41 beat IM Cannabis' score of 0.22 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CNS Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IM Cannabis has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
IM Cannabis	$39.17M	0.04	-$8.10M	-$1.75	N/A

CNS Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. CNS Pharmaceuticals' return on equity of -238.68% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
IM Cannabis	-27.65%	-585.96%	-39.96%

CNS Pharmaceuticals currently has a consensus target price of $20.00, suggesting a potential upside of 323.73%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe CNS Pharmaceuticals is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CNS Pharmaceuticals beats IM Cannabis on 8 of the 14 factors compared between the two stocks.

How does IM Cannabis compare to Cuprina Holdings (Cayman)?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and IM Cannabis (NASDAQ:IMCC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Cuprina Holdings (Cayman) has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market.

In the previous week, Cuprina Holdings (Cayman) and Cuprina Holdings (Cayman) both had 3 articles in the media. Cuprina Holdings (Cayman)'s average media sentiment score of 0.96 beat IM Cannabis' score of 0.22 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cuprina Holdings (Cayman)	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.7% of IM Cannabis shares are held by institutional investors. 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than IM Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$49.89K	126.79	-$3.63M	N/A	N/A
IM Cannabis	$39.17M	0.04	-$8.10M	-$1.75	N/A

Cuprina Holdings (Cayman) has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Cuprina Holdings (Cayman)'s return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
IM Cannabis	-27.65%	-585.96%	-39.96%

Summary

Cuprina Holdings (Cayman) beats IM Cannabis on 7 of the 10 factors compared between the two stocks.

How does IM Cannabis compare to Biodexa Pharmaceuticals?

IM Cannabis (NASDAQ:IMCC) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 5.9% of IM Cannabis shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

IM Cannabis has higher revenue and earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.04	-$8.10M	-$1.75	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

Biodexa Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Biodexa Pharmaceuticals' return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-27.65%	-585.96%	-39.96%
Biodexa Pharmaceuticals	N/A	N/A	N/A

In the previous week, IM Cannabis and IM Cannabis both had 3 articles in the media. Biodexa Pharmaceuticals' average media sentiment score of 0.96 beat IM Cannabis' score of 0.22 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IM Cannabis has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Summary

Biodexa Pharmaceuticals beats IM Cannabis on 5 of the 9 factors compared between the two stocks.

How does IM Cannabis compare to Cardio Diagnostics?

IM Cannabis (NASDAQ:IMCC) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

IM Cannabis has a net margin of -27.65% compared to Cardio Diagnostics' net margin of -36,950.00%. Cardio Diagnostics' return on equity of -78.82% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-27.65%	-585.96%	-39.96%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, IM Cannabis had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for IM Cannabis and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.87 beat IM Cannabis' score of 0.22 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
IM Cannabis	Neutral
Cardio Diagnostics	Very Positive

IM Cannabis has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market.

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cardio Diagnostics has lower revenue, but higher earnings than IM Cannabis. Cardio Diagnostics is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.04	-$8.10M	-$1.75	N/A
Cardio Diagnostics	$10K	592.00	-$6.50M	-$3.38	N/A

Summary

Cardio Diagnostics beats IM Cannabis on 7 of the 13 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCC vs. The Competition

Export

Metric	IM Cannabis	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.54M	$8.33B	$6.52B	$11.98B
Dividend Yield	N/A	2.49%	2.67%	5.62%
P/E Ratio	-0.14	15.99	24.25	24.11
Price / Sales	0.04	6.43	473.59	85.23
Price / Cash	N/A	17.40	43.05	54.72
Price / Book	-0.50	3.56	10.49	6.82
Net Income	-$8.10M	$225.32M	$3.56B	$337.52M
7 Day Performance	-15.91%	-2.83%	-1.98%	-0.98%
1 Month Performance	-1.47%	2.42%	0.71%	1.66%
1 Year Performance	-90.63%	-3.57%	21.91%	26.79%

IM Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCC IM Cannabis	0.2748 of 5 stars	$0.25 +7.1%	N/A	-91.2%	$1.54M	$39.17M	N/A	340	Short Interest Increase Gap Up
GOVX GeoVax Labs	2.2996 of 5 stars	$2.03 -3.3%	$150.00 +7,289.2%	-96.1%	$7.29M	$2.49M	N/A	10	Gap Down
CNSP CNS Pharmaceuticals	3.1616 of 5 stars	$5.24 +6.5%	$20.00 +281.7%	-60.8%	$7.19M	N/A	N/A	5	Positive News Short Interest Increase
CUPR Cuprina Holdings (Cayman)	0.8706 of 5 stars	$2.83 +5.6%	N/A	N/A	$7.03M	$40K	N/A	14	Short Interest Decrease Gap Down
BDRX Biodexa Pharmaceuticals	1.0968 of 5 stars	$3.59 +2.6%	N/A	-94.7%	$6.99M	$470K	N/A	20	Positive News Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCC) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IM Cannabis (IMCC) Competitors

IMCC vs. GOVX, CNSP, CUPR, BDRX, and CDIO

How does IM Cannabis compare to GeoVax Labs?

Summary

How does IM Cannabis compare to CNS Pharmaceuticals?

Summary

How does IM Cannabis compare to Cuprina Holdings (Cayman)?

Summary

How does IM Cannabis compare to Biodexa Pharmaceuticals?

Summary

How does IM Cannabis compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IM Cannabis (IMCC) Competitors

IMCC vs. GOVX, CNSP, CUPR, BDRX, and CDIO

How does IM Cannabis compare to GeoVax Labs?

Which has higher valuation & earnings, IMCC or GOVX?

Do analysts recommend IMCC or GOVX?

Does the media favor IMCC or GOVX?

Do insiders & institutionals believe in IMCC or GOVX?

Is IMCC or GOVX more profitable?

Which has more volatility and risk, IMCC or GOVX?

Summary

How does IM Cannabis compare to CNS Pharmaceuticals?

Which has more volatility & risk, CNSP or IMCC?

Does the media prefer CNSP or IMCC?

Do insiders and institutionals hold more shares of CNSP or IMCC?

Which has higher valuation & earnings, CNSP or IMCC?

Is CNSP or IMCC more profitable?

Do analysts recommend CNSP or IMCC?

Summary

How does IM Cannabis compare to Cuprina Holdings (Cayman)?

Which has more risk and volatility, CUPR or IMCC?

Does the media prefer CUPR or IMCC?

Do insiders and institutionals have more ownership in CUPR or IMCC?

Do analysts rate CUPR or IMCC?

Which has stronger earnings & valuation, CUPR or IMCC?

Is CUPR or IMCC more profitable?

Summary

How does IM Cannabis compare to Biodexa Pharmaceuticals?

Do analysts rate IMCC or BDRX?

Do institutionals and insiders have more ownership in IMCC or BDRX?

Which has stronger valuation and earnings, IMCC or BDRX?

Is IMCC or BDRX more profitable?

Does the media refer more to IMCC or BDRX?

Which has more volatility & risk, IMCC or BDRX?

Summary

How does IM Cannabis compare to Cardio Diagnostics?

Is IMCC or CDIO more profitable?

Do analysts rate IMCC or CDIO?

Does the media favor IMCC or CDIO?

Which has more risk and volatility, IMCC or CDIO?

Do institutionals and insiders hold more shares of IMCC or CDIO?

Which has higher earnings and valuation, IMCC or CDIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools